Gliatilin, 1000 mg/4 ml 4 ml 3 pcs

Gliatin is a neuroprotective.

Pharmacodynamics

It improves nerve impulse transmission in cholinergic neurons; positively influences neuronal membrane plasticity and receptor function. It improves cerebral blood flow, increases metabolic processes in the brain, activates structures of reticular formation of the brain and restores consciousness after traumatic brain injury.

It has a preventive and corrective effect on pathogenetic factors of involutional psycho-organic syndrome such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

On ingestion it is broken down by the action of enzymes into choline and glycerophosphate.

Glyatin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, and on the other hand glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result both have a positive effect on membrane elasticity and on receptor function, which improves synaptic transmission.

Hence, pharmacodynamic studies have shown that Gliatilin acts on synaptic, including cholinergic neurotransmission; neuronal membrane plasticity; and receptor function.

Pharmacokinetics

Absorption when ingested is 88%; easily penetrates through the BBB, accumulates primarily in the brain (brain concentrations reach 45% of blood levels), lungs and liver; 85% is excreted by lungs as carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestine.

It does not affect the reproductive cycle and has no teratogenic and mutagenic effects.

Indications

acute period of TBI with a predominantly brain stem level of damage (impaired consciousness, coma, focal hemispheric symptoms, symptoms of brain stem damage);
ischemic (acute and recovery period) and hemorrhagic stroke (recovery period);
degenerative and involutional psychoorganic syndromes and consequences of cerebrovascular insufficiency, such as primary and secondary disorders of mnestic functions, characterized by memory impairment, confusion, disorientation, decreased motivation, initiative, and ability to concentrate;
changes in the emotional and behavioral sphere: emotional lability, increased irritability, decreased interest, senile pseudomelancholy;
multi-infarct dementia.

Pharmacological effect

Gliatilin is neuroprotective.

Pharmacodynamics

Improves the transmission of nerve impulses in cholinergic neurons; has a positive effect on the plasticity of neuronal membranes and receptor function. Improves cerebral blood flow, enhances metabolic processes in the brain, activates the structures of the reticular formation of the brain and restores consciousness in case of traumatic brain injury.

It has a preventive and corrective effect on such pathogenetic factors of involutional psychoorganic syndrome as changes in the phospholipid composition of neuronal membranes and a decrease in cholinergic activity.

Experimental studies have shown that Gliatilin stimulates the dose-dependent release of acetylcholine under physiological conditions of neurotransmission.

When ingested, it is broken down by enzymes into choline and glycerophosphate.

Gliatilin, on the one hand, being a choline donor, increases the synthesis of acetylcholine and has a positive effect on neurotransmission, on the other hand, glycerophosphate is involved in the synthesis of phosphatidylcholine (membrane phospholipid), as a result, both have a positive effect on membrane elasticity and receptor function, which improves synaptic transmission.

Thus, pharmacodynamic studies have shown that Gliatilin acts on the synaptic, incl. cholinergic neurotransmission; plasticity of the neuronal membrane; receptor function.

Pharmacokinetics

Absorption when taken orally – 88%; easily penetrates the BBB, accumulates mainly in the brain (concentration in the brain reaches 45% of the level in the blood), lungs and liver; 85% is excreted by the lungs in the form of carbon dioxide, the remaining amount (15%) is excreted by the kidneys and through the intestines.

Does not affect the reproductive cycle, does not have teratogenic or mutagenic effects.

Special instructions

Experimental studies have not established the mutagenic effect of the drug.

– Impact on the ability to drive vehicles and operate machinery Gliatilin does not affect the patient’s ability to engage in potentially hazardous activities.

Active ingredient

Choline alphoscerate

Composition

Active ingredient:

choline alfoscerate 1000 mg;

Excipients:

water for injections

Pregnancy

Gliatilin is contraindicated during pregnancy, breastfeeding and childhood.

Contraindications

Hypersensitivity to the components of the drug.

Side Effects

Nausea (as a consequence of dopaminergic activation), in this case the dose of the drug should be reduced. Allergic reactions are possible.

Interaction

Drug interactions with Gliatilin have not been established.

Overdose

Symptoms: nausea.

If this symptom appears, it is recommended to reduce the dose of the drug.

Storage conditions

At a temperature not exceeding 25 °C

Shelf life

5 years

Manufacturer

Italfarmaco S.p.A., Italy